JACQUELINE TRAN: Open Payments
NPI 1831220102 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,905 in 82 payments from 23 companies in 2025. Trend: 2023 $2,938 · 2024 $2,855 · 2025 $2,905
Food & beverage: $2,904Travel & lodging: $1
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 28 | $685 |
| ABBVIE INC. | 14 | $458 |
| AstraZeneca Pharmaceuticals LP | 3 | $252 |
| Corcept Therapeutics | 6 | $252 |
| Lilly USA, LLC | 6 | $186 |
| Madrigal Pharmaceuticals | 1 | $143 |
| Neurocrine BioSciences, Inc. | 1 | $136 |
| Sumitomo Pharma America, Inc. | 1 | $124 |
| Viatris Specialty LLC | 1 | $120 |
| Dexcom, Inc. | 1 | $80 |
Products named: REPATHA, BREZTRI, Korlym, BOTOX, EVENITY, CREON, REZDIFFRA, MOUNJARO.
Industry payments across CA — which companies pay providers there.
